title: Indirect patient expenses for antituberculosis treatment in Tijuana, Mexico: is treatment really free?
abstract: BACKGROUND
  One of the main problems faced by the Mexican National Tuberculosis Program is the high rate of patients abandoning treatment. This study aimed to determine the magnitude of unaccounted costs of tuberculosis (TB) treatment in Tijuana, Mexico.
  
  
  METHODS
  Subjects were recruited at 21 health centres. Patients had confirmed active pulmonary TB, had been on treatment for more than 12 weeks, and were aged 18 years and older. The questionnaire provided information about demographics, past and current episodes of TB, and various categories of expenses.
  
  
  RESULTS
  The study included 180 patients as follows: 48 had been diagnosed with tuberculosis in the past (26.6%) and had either currently relapsed or failed treatment; 160 (88.8%) were under directly observed therapy (DOT); 131 (72.8%) attended a health centre; and the rest received directly observed treatment at home. The daily cost of transportation to the health centre was MXN $25.88 +/- 3.22 (1 USD = 13 MXN). Thirty-two patients (17.8%) had to buy medication at least once, with a monthly medication expense of MXN $440.5 +/- 40.3. Patients receiving DOT at the health centre reported daily food and beverages expenses, spending MXN $56.5 +/- 10.1. Forty-two patients reported laboratory testing expenses, on average MXN $558.8 +/- 85.8 per month. Eighty patients (42.4%) reported expenses on radiographic/ultrasound studies, on average MXN $562.9 +/- 72.1 per six-month regimen. Conclusions TB diagnosis and treatment posed a significant economic burden on patients in terms of both cost and affordability; clinic-based DOT may contribute disproportionately to the costs incurred by patients.
authors.affiliation: Servicio de Medicina Integrada, Hospital General de Tijuana, Mexico. yomogu@hotmail.com
authors.forename: Gema Yolanda
authors.initials: GY
authors.lastname: Guzmán-Montes
authors.forename: Renata Heras
authors.initials: RH
authors.lastname: Ovalles
authors.forename: Rafael
authors.initials: R
authors.lastname: Laniado-Laborín
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000191:economics* / Q000627:therapeutic use; D001628:Beverages / Q000191:economics; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D023801:Directly Observed Therapy / Q000191:economics; D005260:Female; D005502:Food / Q000191:economics; D005102:Health Expenditures; D006801:Humans; D008297:Male; D008800:Mexico; D010349:Patient Compliance; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D014186:Transportation / Q000191:economics; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000191:economics / Q000523:psychology
chemical_list: D000995:Antitubercular Agents